ワクチンの市場規模、シェア、動向分析レポート：タイプ別、投与経路別、適応疾患症別、年齢層別、流通チャネル別、地域別、セグメント予測、2024年～2030年

ワクチン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のワクチン市場規模は2030年までに1,105億4,000万米ドルに達する見込みです。

同市場は、202年から2030年にかけてCAGR 5.74％で拡大する見込みです。成長の背景には、予防接種プログラムの増加や、RSVやクラミジアなどの疾患に対するワクチンの開発があります。公衆衛生上懸念される疾患に対するワクチンへのアクセス改善には大きな進展があった。多くの新しいワクチンが開発され、世界的に配布されるようになり、その結果、数え切れないほどの人命が救われ、さまざまな疾病が予防されるようになった。

さらに、ワクチン市場には、ワクチンへのアクセス改善、新ワクチンの開発、ワクチンの安全性確保を目的としたイニシアチブがいくつか存在します。これらのイニシアチブには、国際機関、政府、民間企業、慈善団体が関与しています。協調と革新を通じて、これらのイニシアチブは世界の健康課題に対処し、公衆衛生の成果を向上させるのに役立っています。例えば、COVAXはCOVIDワクチンへの公平なアクセスを確保することを目的とした世界的イニシアティブです。このイニシアチブは、Gavi、Vaccine Alliance、世界保健機関（WHO）、およびCoalition for Epidemic Preparedness Innovations（CEPI）が共同で主導しています。

2021年に世界保健機関（WHO）加盟国にワクチンを供給するワクチン製造業者は90社以上あるが、供給は依然として、多様な展開可能技術と世界のリーチを持つ10社未満の製造業者に大きく依存しています。このような集中は、特にアフリカと東地中海地域において、地域的な供給不安と市場の健康問題につながっています。米国では、2023年後半にCOVIDワクチン市場が民営化される可能性があると予想されています。この民営化により、COVIDワクチンの価格が上昇し、他のプレーヤーにも市場が開放される可能性があります。例えば、ModernaとPfizer BioNTechの両社は、それぞれのmRNA COVIDワクチンの価格を1回あたり110～130米ドル程度に引き上げる可能性があると発表しています。

ワクチン市場のハイライト

• ワクチンタイプ別では、mRNA分野が2023年に32.32%のシェアを占め、ワクチン市場を独占しました。しかし、予測期間中、サブユニットワクチン分野がCAGR 8.1%と最速の成長が見込まれます。
• 投与経路別では、非経口投与が予測期間を通じてワクチン市場シェアの大半を占めると予測されています。非経口投与は、他の投与経路と比較して汚染リスクを低減するため、このセグメントの優位性に寄与しています。
• 適応疾患別では、ウイルス性疾患セグメントが2023年にワクチン市場で最大のシェアを獲得したが、これは2021年と2022年にCOVID-19ワクチンが多く流通したことが主な要因です。
• 年齢別では、小児科が予測期間中に最も急成長すると予想されます。多くの国で、小児期の定期予防接種の一環として特定の予防接種を受けることを義務付ける国家予防接種プログラムが策定されているからです。
• 販売チャネル別では、薬局が最も急成長すると予測されています。この成長の背景には、患者にとって利用しやすく利便性が向上したこと、薬局にとって収益と利益率が向上する可能性があることが挙げられます。
• 北米地域は予測期間中に最も速いCAGRで成長すると予想されます。この地域は、ファイザー、Moderna、サノフィパスツール、メルクなど少数の主要企業が支配しています。これらの企業は、確立された流通網とワクチン研究開発への多額の投資により、市場で強い存在感を示しています。

目次

第1章 調査手法と範囲

第2章 市場の変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助市場見通し
• 市場動向と展望
• 市場力学
  • 世界中で予防接種の重要性が高まっている
  • 慢性疾患と感染症の負担増大
  • ワクチン開発における技術の進歩
• 市場抑制要因分析
  • ヘルスケアインフラの不足
  • 予防接種の費用
• ビジネス環境分析
  • SWOT分析;要因別（政治・法律、経済・技術）
  • ポーターのファイブフォース分析
• COVID-19の影響分析

第3章 タイプ別ビジネス分析

• タイプ別市場シェア、2023年と2030年
• セグメントダッシュボード
• ワクチン市場タイプ別展望
• 2018年から2030年までの市場規模と予測および動向分析
• サブユニットワクチン
  • サブユニットワクチンのワクチン市場、2018年-2030年
  • 組み換えワクチン
  • 結合ワクチン
  • トキソイドワクチン
• 不活性化
  • 不活化ワクチン市場、2018年-2030年
• 生弱毒化
  • 生弱毒化ワクチン市場、2018年-2030年
• mRNAワクチン
  • mRNAワクチンのワクチン市場、2018年-2030年
• ウイルスベクターワクチン
  • ウイルスベクターワクチンのワクチン市場、2018年-2030年

第4章 投与経路別ビジネス分析

• 投与経路の市場シェア、2023年と2030年
• セグメントダッシュボード
• 投与経路別ワクチン市場の見通し
• 2018年から2030年までの市場規模と予測および動向分析
• 経口
  • 経口ワクチン市場、2018年-2030年
• 非経口
  • 非経口ワクチン市場、2018年-2030年
• 経鼻
  • 経鼻ワクチン市場、2018年-2030年

第5章 疾患適応症別ビジネス分析

• 疾患適応症市場シェア、2023年および2030年
• セグメントダッシュボード
• 疾患適応症別ワクチン市場の見通し
• 2018年から2030年までの市場規模と予測および動向分析
• ウイルス性疾患
  • ウイルス性疾患ワクチン市場、2018年-2030年
  • 肝炎
  • インフルエンザ
  • HPV
  • MMR
  • ロタウイルス
  • 帯状疱疹
  • COVID-19
  • その他
• 細菌ワクチン
  • 細菌ワクチンのワクチン市場、2018年-2030年
  • 髄膜炎菌感染症
  • 肺炎球菌感染症
  • 二酸化ケイ素
  • その他
• がんワクチン
  • がんワクチンのワクチン市場、2018年-2030年
• アレルギーワクチン
  • アレルギーワクチンのワクチン市場、2018年-2030年

第6章 年齢グループ別ビジネス分析

• 年齢グループ別市場シェア、2023年および2030年
• セグメントダッシュボード
• 年齢層別ワクチン市場の見通し
• 2018年から2030年までの市場規模と予測および動向分析
• 小児
  • 小児のワクチン市場、2018年-2030年
• 成人
  • 成人のワクチン市場、2018年-2030年

第7章 流通チャネル別ビジネス分析

• 流通チャネル市場シェア、2023年および2030年
• セグメントダッシュボード
• 流通チャネル別ワクチン市場の見通し
• 2018年から2030年までの市場規模と予測および動向分析
• 病院および薬局
  • 病院および小売薬局ワクチン市場、2018年-2030年
• 政府サプライヤー
  • 政府サプライヤーワクチン市場2018-2030
• その他
  • その他ワクチン市場、2018年-2030年

第8章 地域別ビジネス分析

• 地域別ワクチン市場シェア、2023年と2030年
• 北米
  • 北米ワクチン市場2018-2030
  • 米国
  • カナダ
• 欧州
  • 欧州のワクチン市場2018-2030
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋ワクチン市場、2018年-2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカのワクチン市場、2018年-2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカワクチン市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参入企業の概要
• 財務実績
• 参入企業
  • マーケットリーダー
  • ワクチン市場シェア分析、2023年
  • 企業プロファイル
  • 戦略マッピング
    • Serum Institute of India Pvt. Ltd.
    • Seqirus
    • Sanofi
    • GSK Plc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Moderna Inc.
    • Sinovac
    • BioNTech SE
    • AstraZeneca
  • 戦略マッピング

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Vaccine Market, by Region, 2018 - 2030 (USD Billion)
• Table 4 Global Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 5 Global Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 6 Global Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 7 Global Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 8 Global Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 9 North America Vaccine Market, by Country, 2018 - 2030 (USD Billion)
• Table 10 North America Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 11 North America Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 12 North America Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 13 North America Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 14 North America Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 15 U.S. Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 16 U.S. Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 17 U.S. Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 18 U.S. Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 19 U.S. Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 20 Canada Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 21 Canada Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 22 Canada Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 23 Canada Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 24 Canada Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 25 Europe Vaccine Market, by Country, 2018 - 2030 (USD Billion)
• Table 26 Europe Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 27 Europe Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 28 Europe Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 29 Europe Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 30 Europe Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 31 Germany Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 32 Germany Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 33 Germany Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 34 Germany Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 35 Germany Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 36 UK Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 37 UK Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 38 UK Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 39 UK Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 40 UK Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 41 France Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 42 France Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 43 France Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 44 France Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 45 France Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 46 Italy Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 47 Italy Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 48 Italy Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 49 Italy Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 50 Italy Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 51 Spain Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 52 Spain Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 53 Spain Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 54 Spain Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 55 Spain Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 56 Denmark Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 57 Denmark Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 58 Denmark Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 59 Denmark Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 60 Denmark Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 61 Sweden Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 62 Sweden Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 63 Sweden Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 64 Sweden Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 65 Sweden Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 66 Norway Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 67 Norway Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 68 Norway Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 69 Norway Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 70 Norway Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 71 Asia Pacific Vaccine Market, by Country, 2018 - 2030 (USD Billion)
• Table 72 Asia Pacific Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 73 Asia Pacific Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 74 Asia Pacific Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 75 Asia Pacific Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 76 Asia Pacific Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 77 China Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 78 China Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 79 China Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 80 China Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 81 China Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 82 Japan Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 83 Japan Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 84 Japan Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 85 Japan Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 86 Japan Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 87 India Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 88 India Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 89 India Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 90 India Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 91 India Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 92 South Korea Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 93 South Korea Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 94 South Korea Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 95 South Korea Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 96 South Korea Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 97 Australia Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 98 Australia Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 99 Australia Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 100 Australia Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 101 Australia Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 102 Thailand Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 103 Thailand Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 104 Thailand Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 105 Thailand Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 106 Thailand Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 107 Latin America Vaccine Market, by Country, 2018 - 2030 (USD Billion)
• Table 108 Latin America Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 109 Latin America Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 110 Latin America Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 111 Latin America Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 112 Latin America Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 113 Brazil Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 114 Brazil Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 115 Brazil Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 116 Brazil Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 117 Brazil Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 118 Mexico Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 119 Mexico Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 120 Mexico Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 121 Mexico Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 122 Mexico Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 123 Argentina Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 124 Argentina Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 125 Argentina Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 126 Argentina Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 127 Argentina Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 128 Middle East & Africa Vaccine Market, by Country, 2018 - 2030 (USD Billion)
• Table 129 Middle East & Africa Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 130 Middle East & Africa Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 131 Middle East & Africa Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 132 Middle East & Africa Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 133 Middle East & Africa Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 134 South Africa Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 135 South Africa Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 136 South Africa Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 137 South Africa Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 138 South Africa Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 139 Saudi Arabia Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 140 Saudi Arabia Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 141 Saudi Arabia Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 142 Saudi Arabia Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 143 Saudi Arabia Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 144 UAE Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 145 UAE Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 146 UAE Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 147 UAE Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 148 UAE Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 149 Kuwait Vaccine Market, by Type, 2018 - 2030 (USD Billion)
• Table 150 Kuwait Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 151 Kuwait Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
• Table 152 Kuwait Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
• Table 153 Kuwait Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 154 Financial performance
• Table 155 Key companies undergoing expansions
• Table 156 Key companies undergoing acquisitions
• Table 157 Key companies undergoing collaborations
• Table 158 Key companies launching new products/services
• Table 159 Key companies undergoing partnerships
• Table 160 Key companies undertaking other strategies

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Vaccine Market Segmentation
• Fig. 7 Market Snapshot, 2023
• Fig. 8 Market Trends & Outlook
• Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2023
• Fig. 15 Global Vaccine Market: By Type, Movement Analysis
• Fig. 16 Global Vaccine Market, for Subunit Vaccines, 2018 - 2030 (USD Billion)
• Fig. 17 Global Vaccine Market, for Recombinant vaccines, 2018 - 2030 (USD Billion)
• Fig. 18 Global Vaccine Market, for Conjugate Vaccines, 2018 - 2030 (USD Billion)
• Fig. 19 Global Vaccine Market, for Toxoid vaccines, 2018 - 2030 (USD Billion)
• Fig. 20 Global Vaccine Market, for Inactivated, 2018 - 2030 (USD Billion)
• Fig. 21 Global Vaccine Market, for Live Attenuated2018 - 2030 (USD Billion)
• Fig. 22 Global Vaccine Market, for mRNA vaccines, 2018 - 2030 (USD Billion)
• Fig. 23 Global Vaccine Market, for Viral vector vaccines, 2018 - 2030 (USD Billion)
• Fig. 24 Global Vaccine Market: By Route of Administration, Movement Analysis
• Fig. 25 Global Vaccine Market, for Oral, 2018 - 2030 (USD Billion)
• Fig. 26 Global Vaccine Market, for Parenteral, 2018 - 2030 (USD Billion)
• Fig. 27 Global Vaccine Market, for Nasal2018 - 2030 (USD Billion)
• Fig. 28 Global Vaccine Market: Disease Indication, Movement Analysis
• Fig. 29 Global Vaccine Market, for Viral Diseases, 2018 - 2030 (USD Billion)
• Fig. 30 Global Vaccine Market, for Hepatitis, 2018 - 2030 (USD Billion)
• Fig. 31 Global Vaccine Market, for Influenza2018 - 2030 (USD Billion)
• Fig. 32 Global Vaccine Market, for HPV, 2018 - 2030 (USD Billion)
• Fig. 33 Global Vaccine Market, for MMR, 2018 - 2030 (USD Billion)
• Fig. 34 Global Vaccine Market, for Rotavirus, 2018 - 2030 (USD Billion)
• Fig. 35 Global Vaccine Market, for Herpes Zoster, 2018 - 2030 (USD Billion)
• Fig. 36 Global Vaccine Market, for COVID-19, 2018 - 2030 (USD Billion)
• Fig. 37 Global Vaccine Market, for Bacterial Vaccines, 2018 - 2030 (USD Billion)
• Fig. 38 Global Vaccine Market, for Meningococcal Diseases, 2018 - 2030 (USD Billion)
• Fig. 39 Global Vaccine Market, for Pneumococcal diseases, 2018 - 2030 (USD Billion)
• Fig. 40 Global Vaccine Market, for DPT, 2018 - 2030 (USD Billion)
• Fig. 41 Global Vaccine Market, for Others, 2018 - 2030 (USD Billion)
• Fig. 42 Global Vaccine Market, for Cancer Vaccines, 2018 - 2030 (USD Billion)
• Fig. 43 Global Vaccine Market, for Allergy Vaccines, 2018 - 2030 (USD Billion)
• Fig. 44 Global Vaccine Market: Age Group, Movement Analysis
• Fig. 45 Global Vaccine Market, for Pediatric,2018 - 2030 (USD Billion)
• Fig. 46 Global Vaccine Market, for Adult ,2018 - 2030 (USD Billion)
• Fig. 47 Global Vaccine Market: Distribution Channel, Movement Analysis
• Fig. 48 Global Vaccine Market, for Hospital & Retail Pharmacies,2018 - 2030 (USD Billion)
• Fig. 49 Global Vaccine Market, for Government Suppliers,2018 - 2030 (USD Billion)
• Fig. 50 Global Vaccine Market, for Others2018 - 2030 (USD Billion)
• Fig. 51 Regional Marketplace: Key Takeaways Vaccine Market,
• Fig. 52 Regional Outlook, 2023 & 2030 Vaccine Market,
• Fig. 53 Global Vaccine Market: Region Movement Analysis
• Fig. 54 North America Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 55 U.S. Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 56 Canada Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 57 Europe Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 58 Germany Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 59 UK Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 60 France Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 61 Italy Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 62 Spain Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 63 Denmark Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 64 Sweden Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 65 Norway Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 66 Asia Pacific Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 67 Japan Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 68 China Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 69 India Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 70 Australia Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 71 South Korea Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 72 Thailand Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 73 Latin America Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 74 Brazil Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 75 Mexico Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 76 Argentina Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 77 Middle East and Africa Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 78 South Africa Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 79 Saudi Arabia Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 80 UAE Vaccine Market, 2018 - 2030 (USD Billion)
• Fig. 81 Kuwait Vaccine Market, 2018 - 2030 (USD Billion)

Vaccine Market Growth & Trends:

The global vaccine market size is expected to reach USD 110.54 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.74% from 202 to 2030. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Vaccine Market Report Highlights:

• By type, the mRNA segment dominated the vaccine market with a share of 32.32% in 2023. However, the subunit vaccine segment is expected to grow at the fastest CAGR of 8.1% during the forecast period
• By route of administration, the parenteral administration is anticipated to capture the majority of the vaccine market share throughout the forecast period. Parenteral administration reduces the risk of contamination compared to other routes of administration thus contributing to the segments' dominance
• By disease indication, the viral diseases segment captured the largest share of the vaccine market in 2023, majorly attributed to the high distribution of COVID-19 vaccines during 2021 and 2022
• By age, pediatrics is expected to witness the fastest growth during the forecast period, as many countries have established national immunization programs that require children to receive certain shots as part of routine childhood vaccinations
• By distribution channel, pharmacies are anticipated to be the fastest-growing segment. This growth can be attributed to the increased accessibility and convenience for patients, and the potential for increased revenue and profitability for pharmacies
• North America region is expected to grow at the fastest CAGR during the forecast period. The region is dominated by a few key players, including Pfizer, Moderna, Sanofi Pasteur, and Merck. These companies have a strong presence in the market, with established distribution networks and significant investment in vaccine research and development

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Route of Administration
  • 1.2.3. Disease Indication
  • 1.2.4. Age Group
  • 1.2.5. Distribution Channel
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Market Variables, Trends, & Scope

• 2.1. Market Segmentation and Scope
• 2.2. Market Lineage Outlook
  • 2.2.1. Parent Market Outlook
  • 2.2.2. Related/Ancillary Market Outlook
• 2.3. Market Trends and Outlook
• 2.4. Market Dynamics
  • 2.4.1. Rise in the importance of immunization across the globe
  • 2.4.2. Growing Burden of Chronic and Infectious Diseases
  • 2.4.3. Technology advancements in the vaccination development
• 2.5. Market Restraint Analysis
  • 2.5.1. Lack of healthcare infrastructure
  • 2.5.2. Cost of immunization
• 2.6. Business Environment Analysis
  • 2.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 2.6.2. Porter's Five Forces Analysis
• 2.7. COVID-19 Impact Analysis

Chapter 3. Type Business Analysis

• 3.1. Type Market Share, 2023 & 2030
• 3.2. Segment Dashboard
• 3.3. Vaccines Market by Type Outlook
• 3.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 3.5. Subunit Vaccines
  • 3.5.1. Vaccine Market for Subunit Vaccines, 2018 - 2030 (USD Billion)
  • 3.5.2. Recombinant vaccines
    • 3.5.2.1. Vaccine Market for Recombinant vaccines, 2018 - 2030 (USD Billion)
  • 3.5.3. Conjugate Vaccines
    • 3.5.3.1. Vaccine Market for Conjugate vaccines, 2018 - 2030 (USD Billion)
  • 3.5.4. Toxoid vaccines
    • 3.5.4.1. Vaccine Market for Toxoid vaccines, 2018 - 2030 (USD Billion)
• 3.6. Inactivated
  • 3.6.1. Vaccine Market for Inactivated, 2018 - 2030 (USD Billion)
• 3.7. Live Attenuated
  • 3.7.1. Vaccine Market for Live Attenuated, 2018 - 2030 (USD Billion)
• 3.8. mRNA vaccines
  • 3.8.1. Vaccine Market for mRNA vaccines, 2018 - 2030 (USD Billion)
• 3.9. Viral vector vaccines
  • 3.9.1. Vaccine Market for Viral vector vaccines, 2018 - 2030 (USD Billion)

Chapter 4. Route Of Administration Business Analysis

• 4.1. Route of administration Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Vaccines Market by Route of administration Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Oral
  • 4.5.1. Vaccine Market for Oral, 2018 - 2030 (USD Billion)
• 4.6. Parenteral
  • 4.6.1. Vaccine Market for Parenteral, 2018 - 2030 (USD Billion)
• 4.7. Nasal
  • 4.7.1. Vaccine Market for Nasal, 2018 - 2030 (USD Billion)

Chapter 5. Disease Indication Business Analysis

• 5.1. Disease Indication Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Vaccines Market by Disease Indication Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Viral Diseases
  • 5.5.1. Vaccine Market for Viral Diseases, 2018 - 2030 (USD Billion)
  • 5.5.2. Hepatitis
    • 5.5.2.1. Vaccine Market for Hepatitis, 2018 - 2030 (USD Billion)
  • 5.5.3. Influenza
    • 5.5.3.1. Vaccine Market for Influenza, 2018 - 2030 (USD Billion)
  • 5.5.4. HPV
    • 5.5.4.1. Vaccine Market for HPV, 2018 - 2030 (USD Billion)
  • 5.5.5. MMR
    • 5.5.5.1. Vaccine Market for MMR, 2018 - 2030 (USD Billion)
  • 5.5.6. Rotavirus
    • 5.5.6.1. Vaccine Market for Rotavirus, 2018 - 2030 (USD Billion)
  • 5.5.7. Herpes Zoster
    • 5.5.7.1. Vaccine Market for Herpes Zoster, 2018 - 2030 (USD Billion)
  • 5.5.8. COVID-19
    • 5.5.8.1. Vaccine Market for Covid-19, 2018 - 2030 (USD Billion)
  • 5.5.9. Others
    • 5.5.9.1. Vaccine Market for Others, 2018 - 2030 (USD Billion)
• 5.6. Bacterial Vaccines
  • 5.6.1. Vaccine Market for Bacterial Vaccines, 2018 - 2030 (USD Billion)
  • 5.6.2. Meningococcal Diseases
    • 5.6.2.1. Vaccine Market for Meningococcal Diseases, 2018 - 2030 (USD Billion)
  • 5.6.3. Pneumococcal Diseases
    • 5.6.3.1. Vaccine Market for Pneumococcal Diseases, 2018 - 2030 (USD Billion)
  • 5.6.4. DPT
    • 5.6.4.1. Vaccine Market for DPT, 2018 - 2030 (USD Billion)
  • 5.6.5. Others
    • 5.6.5.1. Vaccine Market for Others, 2018 - 2030 (USD Billion)
• 5.7. Cancer Vaccines
  • 5.7.1. Vaccine Market for Cancer Vaccines, 2018 - 2030 (USD Billion)
• 5.8. Allergy Vaccines
  • 5.8.1. Vaccine Market for Allergy Vaccines, 2018 - 2030 (USD Billion)

Chapter 6. Age Group Business Analysis

• 6.1. Age Group Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Vaccines Market by Age Group Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Pediatric
  • 6.5.1. Vaccine Market for Pediatric, 2018 - 2030 (USD Billion)
• 6.6. Adult
  • 6.6.1. Vaccine Market for Adult, 2018 - 2030 (USD Billion)

Chapter 7. Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Vaccines Market by Distribution Channel Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Hospital & Retail Pharmacies
  • 7.5.1. Vaccine Market for Hospital & Retail Pharmacies, 2018 - 2030 (USD Billion)
• 7.6. Government Suppliers
  • 7.6.1. Vaccine Market for Government Suppliers 2018 - 2030 (USD Billion)
• 7.7. Others
  • 7.7.1. Vaccine Market for Others, 2018 - 2030 (USD Billion)

Chapter 8. Regional Business Analysis

• 8.1. Vaccine Market Share By Region, 2023 & 2030
• 8.2. North America
  • 8.2.1. North America Vaccines Market 2018 - 2030 (USD Billion)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Target Disease Prevalence
    • 8.2.2.3. Competitive Scenario
    • 8.2.2.4. Regulatory Framework
    • 8.2.2.5. Reimbursement Scenario
    • 8.2.2.6. U.S. Vaccine Market 2018 - 2030 (USD Billion)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. Canada Vaccine Market 2018 - 2030 (USD Billion)
• 8.3. Europe
  • 8.3.1. Europe Vaccines Market 2018 - 2030 (USD Billion)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. Reimbursement Scenario
    • 8.3.2.6. Germany Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. UK Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. France Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. Italy Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Spain Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Denmark Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Sweden Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Norway Vaccine Market 2018 - 2030 (USD Billion)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Vaccine Market, 2018 - 2030 (USD Billion)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Reimbursement Scenario
    • 8.4.2.6. Japan Vaccine Market 2018 - 2030 (USD Billion)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. China Vaccine Market 2018 - 2030 (USD Billion)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. India Vaccine Market 2018 - 2030 (USD Billion)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. South Korea Vaccine Market 2018 - 2030 (USD Billion)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. Australia Vaccine Market 2018 - 2030 (USD Billion)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Thailand Vaccine Market 2018 - 2030 (USD Billion)
• 8.5. Latin America
  • 8.5.1. Latin America Vaccine Market, 2018 - 2030 (USD Billion)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Reimbursement Scenario
    • 8.5.2.6. Brazil Vaccine Market 2018 - 2030 (USD Billion)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Mexico Vaccine Market 2018 - 2030 (USD Billion)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Reimbursement Scenario
    • 8.5.4.6. Argentina Vaccine Market 2018 - 2030 (USD Billion)
• 8.6. MEA
  • 8.6.1. MEA Vaccine Market, 2018 - 2030 (USD Billion)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Reimbursement Scenario
    • 8.6.2.6. South Africa Vaccine Market 2018 - 2030 (USD Billion)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. Saudi Arabia Vaccine Market 2018 - 2030 (USD Billion)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. UAE Vaccine Market 2018 - 2030 (USD Billion)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. Kuwait Vaccine Market 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Participant's overview
• 9.2. Financial performance
• 9.3. Participant categorization
  • 9.3.1. Market Leaders
  • 9.3.2. Vaccine Market Share Analysis, 2023
  • 9.3.3. Company Profiles
    • 9.3.3.1. Serum Institute of India Pvt. Ltd.
    • 9.3.3.1.1. Company Overview
    • 9.3.3.1.2. Financial Performance
    • 9.3.3.1.3. Product Benchmarking
    • 9.3.3.1.4. Strategic Initiatives
    • 9.3.3.2. Seqirus
    • 9.3.3.2.1. Company Overview
    • 9.3.3.2.2. Financial Performance
    • 9.3.3.2.3. Product Benchmarking
    • 9.3.3.2.4. Strategic Initiatives
    • 9.3.3.3. Sanofi
    • 9.3.3.3.1. Company Overview
    • 9.3.3.3.2. Financial Performance
    • 9.3.3.3.3. Product Benchmarking
    • 9.3.3.3.4. Strategic Initiatives
    • 9.3.3.4. GSK Plc.
    • 9.3.3.4.1. Company Overview
    • 9.3.3.4.2. Financial Performance
    • 9.3.3.4.3. Product Benchmarking
    • 9.3.3.4.4. Strategic Initiatives
    • 9.3.3.5. Merck & Co., Inc.
    • 9.3.3.5.1. Company Overview
    • 9.3.3.5.2. Financial Performance
    • 9.3.3.5.3. Product Benchmarking
    • 9.3.3.5.4. Strategic Initiatives
    • 9.3.3.6. Pfizer Inc.
    • 9.3.3.6.1. Company Overview
    • 9.3.3.6.2. Financial Performance
    • 9.3.3.6.3. Product Benchmarking
    • 9.3.3.6.4. Strategic Initiatives
    • 9.3.3.7. Moderna Inc.
    • 9.3.3.7.1. Company Overview
    • 9.3.3.7.2. Financial Performance
    • 9.3.3.7.3. Product Benchmarking
    • 9.3.3.7.4. Strategic Initiatives
    • 9.3.3.8. Sinovac
    • 9.3.3.8.1. Company Overview
    • 9.3.3.8.2. Financial Performance
    • 9.3.3.8.3. Product Benchmarking
    • 9.3.3.8.4. Strategic Initiatives
    • 9.3.3.9. BioNTech SE
    • 9.3.3.9.1. Company Overview
    • 9.3.3.9.2. Financial Performance
    • 9.3.3.9.3. Product Benchmarking
    • 9.3.3.9.4. Strategic Initiatives
    • 9.3.3.10. AstraZeneca
    • 9.3.3.10.1. Company Overview
    • 9.3.3.10.2. Financial Performance
    • 9.3.3.10.3. Product Benchmarking
    • 9.3.3.10.4. Strategic Initiatives
  • 9.3.4. Strategy Mapping
    • 9.3.4.1. Expansion
    • 9.3.4.2. Acquisition
    • 9.3.4.3. Collaborations
    • 9.3.4.4. Product/Service Launch
    • 9.3.4.5. Partnerships
    • 9.3.4.6. Others